Blog
RSS FeedPosted by Michael Wonder on 01 Nov 2022
First immunotherapy for patients with a potentially life threatening type of non-melanoma skin cancer now available on the PBS
1 November 2022 - Australians with a potentially life-threatening type of non-melanoma skin cancer will for the first time, have ...
Posted by Michael Wonder on 10 Oct 2022
Ground breaking platform launched for Aboriginal and Torres Strait Islander people affected by cancer
10 October 2022 - Australia’s first comprehensive cancer website developed by and for Indigenous Australians has officially launched today in a ...
Posted by Michael Wonder on 04 Oct 2022
Landmark PBS listing for treatment of gastro-oesophageal cancers
1 October 2022 - From 1 October, Australians with advanced or metastatic gastro-oesophageal cancers will have access to new treatment through ...
Posted by Michael Wonder on 26 Sep 2022
Patients will pay less for critical medicines including ‘miracle’ cancer drug
26 September 2022 - Australians will have cheaper access to medicines for migraines, arthritis, bipolar, stomach ulcers and several cancers. ...
Posted by Michael Wonder on 10 Sep 2022
Your money or your life? Cancer’s crushing cost
10 September 2022 - The first thing many cancer patients see when they arrive at the oncology ward is the EFTPOS ...
Posted by Michael Wonder on 09 Sep 2022
Rare cancer sufferers fight to get drugs on PBS
9 September 2022 - People with rare cancers are being forced to sell their homes, raid their superannuation and fundraise ...
Posted by Michael Wonder on 05 Sep 2022
Review of Efficient Funding of Chemotherapy Program - interim report
5 September 2022 - The Efficient Funding of Chemotherapy review seeks to investigate current processes involved in the production, distribution ...
Posted by Michael Wonder on 01 Sep 2022
Antengene announces Xpovia included for reimbursement by the PBS in Australia for the treatment of patients with relapsed and/or refractory multiple myeloma
1 September 2022 - Xpovio (selinexor) is the first and only selective inhibitor of nuclear export (SINE) inhibitor approved by the ...
Posted by Michael Wonder on 01 Sep 2022
PBS listing for ovarian cancer and kidney disease
1 September 2022 - From 1 September 2022, Australians will have access to new and expanded medicines on the Pharmaceutical Benefits ...
Posted by Michael Wonder on 28 Aug 2022
Ovarian cancer drug that costs up to $130k will soon be affordable for hundreds of patients
28 August 2022 - A drug that works to prolong survival for some patients with advanced ovarian cancer is being ...
Posted by Michael Wonder on 19 Aug 2022
1 September 2022 updates as part of the digital transformation of authority required (written) PBS listings
19 August 2022 - From 1 September 2022, the PBS listings for certain cancer medicines will be updated as part of ...
Posted by Michael Wonder on 03 Jul 2022
Rare blood cancer drug Brukinsa to be listed for the first time on Pharmaceutical Benefits Scheme
1 July 2022 - Graeme Anderson had just finished seven days of night shift when he first noticed something didn’t feel ...
Posted by Michael Wonder on 30 Jun 2022
PBS listing for ‘Australian success story’ blood cancer drug
1 July 2022 - A pill that removes the need for chemotherapy for some cancer sufferers has been put on ...
Posted by Michael Wonder on 19 Jun 2022
Current issues in health technology assessment of cancer therapies: a survey of stakeholders and opinion leaders in Australia
17 June 2022 - The aim of this study was to find ways of bridging the gap in opinions concerning health ...
Posted by Michael Wonder on 01 May 2022
Cost of some life-saving drugs to be slashed
1 May 2022 - Changes to the PBS could save some Australians as much as $2.5 million per treatment, as others ...